Stockwinners Market Radar for April 25, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Zyversa Therapeutics Inc trading halted, news pending

19:50 EDT iSun trading halted, news pending

18:32 EDT Microsoft says near-term AI demand 'a bit higher than capacity'

18:08 EDT Microsoft sees Q4 Intelligent Cloud revenue $28.4B-$28.7B - Sees Q4 More Personal Computing revenue $15.2B-$15.6B. Sees Q4 Productivity and Business Processes revenue $19.9B-$20.2B. Sees Q4 Office 365 growth 14%. Sees Q4 LinkedIn revenue growth mid to high single digits. Sees Q4 Azure revenue growth 30%-31%. Sees Q4 Dynamics revenue growth in low to mid teens. Sees Q4 CapEx up "materially," sequentially. Sees Q4 currency impacting sales by less than 1%. Sees Q4: COGS $19.6B-$19.8B; OpEx $17.15B-$17.25B; tax rate ~18%.

17:45 EDT Community Healthcare raises quarterly dividend to 46c per share - Community Healthcare has increased its common stock cash dividend for Q1 2024. This dividend in the amount of 46c per share is payable on May 24 to shareholders of record on May 10 and equates to an annualized dividend of $1.84 per share.

17:10 EDT Marathon Digital increases FY24 hash rate target to 50 EH/s - Marathon Digital announced that the company is increasing its hash rate target for fiscal year 2024 from 35-37 EH/s to 50 EH/s. Marathon began 2024 with approximately 24.7 EH/s energized and had been planning to grow its hash rate by approximately 46% to 35-37 EH/s by the end of the year. Based on current machine orders and available capacity following its recent acquisitions, Marathon now expects to grow its operations to approximately 50 EH/s by the end of 2024. The new target represents approximately 100% growth in hash rate during 2024 and is fully funded based on Marathon's current liquidity position.

17:06 EDT Alphabet says has clear path to AI monetization - Says strong quarter led by search YouTube and cloud. Says seeing increase of search use. Says over 15 products have over half a billion users. Says focused on cash structures and procurement. Says has clear path to AI monetization. Says . Says YouTube TV has more than 8M paid subscribers. Says pause advertisements are driving strong brand lift results and commanding premium pricing. Comments taken from Q1 earnings conference call.

17:01 EDT Parker-Hannifin increases quarterly cash dividend 10% to $1.63 per share - Parker Hannifin has declared a quarterly cash dividend of $1.63 per share of common stock to shareholders of record as of May 10, payable June 7.

16:48 EDT Aligos Therapeutics to present data on ALG-097558 at ESCMID - Aligos Therapeutics announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases, or ESCMID, 2024, being held April 27-30 in Barcelona, Spain. The presentation highlights ALG-097558 Phase 1 data showing that single and multiple doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect.

16:45 EDT Recon Technology announces 1-for-18 reverse stock split - Recon Technology announced that the company's shareholders approved on March 29, 2024 to effect a reverse stock split of the company's Class A ordinary shares at the ratio of one-for-eighteen with the market effective date of May 1, 2024. The objective of the reverse stock split is to enable the company to regain compliance with the NASDAQ Marketplace Rule 5550(a)(2) and maintain its listing on Nasdaq. Beginning with the opening of trading on May 1, 2024, the company's ordinary shares will trade on the NASDAQ Capital Market on a split-adjusted basis, under the same symbol "RCON" but under a new CUSIP Number, G7415M132. The reverse stock split will reduce the number of Class A ordinary shares issued and outstanding from approximately 141,803,218 to approximately 7,877,956.

16:44 EDT Biogen receives positive CHMP opinion for TOFIDENCE - Biogen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for TOFIDENCE, a biosimilar monoclonal antibody referencing ROACTEMRA. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19. The CHMP's positive opinion will now be referred to the European Commission, which will decide whether to grant marketing authorization for TOFIDENCE. If a marketing authorization is granted by the EC, TOFIDENCE will be an addition to the existing biosimilars portfolio of three widely prescribed anti-TNF biosimilars commercialized by Biogen in Europe: BENEPALI, IMRALDI and FLIXABI, offering an extension to the cost-effective treatment options with an additional mechanism of action. "The positive CHMP recommendation for TOFIDENCE marks another positive step toward helping more people with inflammatory and immune-mediated conditions gain access to leading therapies," said Ian Henshaw, Global Head of Biosimilars at Biogen. "Positive CHMP recommendation for TOFIDENCE is testament to our continuing efforts to develop and deliver high-quality and proven biologic medicines to more patients, healthcare providers and healthcare systems in Europe."

16:40 EDT Employers Holdings raises quarterly dividend to 30c per share - On April 24, 2024, the Companys Board of Directors declared a regular quarterly dividend of $0.30 per share, an increase of 7% from the prior quarterly dividend of $0.28 per share. The dividend is payable on May 22, 2024 to stockholders of record as of May 8, 2024.

16:31 EDT Ingersoll-Rand increases buyback authorization to $1.0B - Ingersoll Rand's Board of Directors approved an incremental $1B increase to the share repurchase authorization. Aligned with the company's previously communicated capital allocation strategy, Ingersoll Rand estimates it will fully utilize the remainder of the existing $750M repurchase authorization by the end of fiscal year 2024. The additional share repurchase authorization is consistent with the company's holistic capital allocation philosophy and focus on shareholder value creation.

16:20 EDT Eastern Bankshares says James Fitzgerald intends to retire as CFO, CAO - The company announced that James Fitzgerald intends to retire from his role as Chief Financial Officer, Chief Administrative Officer and Treasurer of the company and as Chief Financial Officer, Chief Administrative Officer and Vice Chair of Eastern Bank after 12 years of dedicated service. Fitzgerald will continue to serve in his roles until a successor is appointed, and will then serve in a senior advisory role throughout the planned merger and integration with Cambridge and Cambridge Trust Company and previously announced leadership transitions related to the merger. As part of the search process to help identify the next CFO, Eastern has retained executive search firm Korn Ferry.

16:15 EDT Carlisle sees FY24 revenue up 10%, consensus $4.89B - Sees FY24 adjusted EBITDA margins expanding over 100 bps

16:10 EDT Alphabet reports $716M in employee severance and related charges in Q1 - Alphabet said: "Compensation expenses included employee severance and related charges for the three months ended March 31, 2024 of $716M, a $1.3B decrease in severance and related charges as compared to the three months ended March 31, 2023. For the first quarter of 2024, these charges are included within cost of revenues, research and development, sales and marketing, and general and administrative expenses in the amounts of $153M, $247M, $217M, and $99M, respectively.

16:09 EDT Atlassian says Scott Farquhar to step down as co-CEO effective August 31 - Atlassian announced co-founder Scott Farquhar will step down as co-CEO effective August 31, 2024, with co-founder Mike Cannon Brookes continuing to lead Atlassian as CEO. "While it's a difficult decision to step away, I do so knowing Atlassian is exceptionally positioned to take hold of the massive opportunities at its feet. We have a strong leadership team, and great momentum around cloud, enterprise, and now, AI," said Farquhar. Scott's last day as co-CEO will be August 31, 2024. He will continue as an active Board member and assume a special advisor role.

16:08 EDT Alphabet CEO says results 'strong' in Search, YouTube and Cloud - Sundar Pichai, CEO, said: "Our results in the first quarter reflect strong performance from Search, YouTube and Cloud. We are well under way with our Gemini era and there's great momentum across the company. Our leadership in AI research and infrastructure, and our global product footprint, position us well for the next wave of AI innovation." Ruth Porat, President and Chief Investment Officer; CFO said: "Our strong financial results for the first quarter reflect revenue strength across the company and ongoing efforts to durably reengineer our cost base. We delivered revenues of $80.5 billion, up 15% year-on-year, and operating margin expansion."

16:07 EDT T-Mobile reports Q1 postpaid net account additions 218K - The company states: "Postpaid net account additions of 218 thousand, best in industry. Postpaid net customer additions of 1.2 million, best in industry. Postpaid phone net customer additions of 532 thousand, best in industry and higher share of industry net adds year-over-year. Postpaid phone churn of 0.86%, matches record low for Q1."

16:05 EDT Alphabet approves initiation of cash dividend program - Alphabet's board of directors approved the initiation of a cash dividend program, and declared a cash dividend of 20c per share that will be paid on June 1 to stockholders of record as of June 10, 2024, on each of the company's Class A, Class B, and Class C shares. The company intends to pay quarterly cash dividends in the future, subject to review and approval by the company's board of directors in its sole discretion.

16:04 EDT Microsoft returned $8.4B to shareholders via dividends, buybacks in Q3

16:02 EDT Microsoft reports Q3 Intelligent Cloud revenue $26.7B - Reports Q3 Devices revenue down 17%. Reports LinkedIn revenue up 10%. Reports Xbox content and services revenue up 62%.

15:41 EDT iSun announces rescission of reverse stock split - iSun announced that its Board of Directors has approved the rescission of the previously announced reverse stock split. The decision to rescind the reverse stock split was made after careful consideration and analysis of market conditions, and the company's financial performance outlook. The Board of Directors believes that this action is in the best interest of the company and its shareholders. As a result of the rescission, the reverse stock split that was previously approved will not be implemented, and the company's outstanding shares will remain unaffected by the split.

15:21 EDT Cullen/Frost updates non-owner-occupied commercial real estate loan models - In a regulatory filing, Cullen/Frost Bankers said that, in Q1, it updated its non-owner-occupied commercial real estate loan models as well as its consumer and other loan models. "Our prior non-owner-occupied commercial real estate loan models were legacy models developed for stress-testing purposes by a third-party using external market data," the company said in the filing. "The updated non-owner-occupied commercial real estate loan models are now based on internal historical loan data and risk grade information and the modeling processes are now consistent with those used with our other commercial loan models. Our prior consumer and other loan models relied upon certain components that did not use loan level attributes and were less sensitive to macroeconomic variables. The updated consumer and other loan models are now based on internal historical loan data and utilize more loan-level attributes and the modeling processes are now consistent with those used with our consumer real estate loan models. The overall approximate impact of the model updates during the first quarter was a $7.2 million increase ($6.2 million related to non-owner-occupied commercial real estate loans and $923 thousand related to consumer and other loans) in modeled expected credit losses on loans; however, the impact of this increase was largely offset by reductions in qualitative adjustments as some of the risks to which those qualitative adjustments related are now considered and incorporated in the updated models."

14:08 EDT Petrobras trading resumes

13:35 EDT Petrobras trading halted, news pending

13:00 EDT Avery Dennison board increases quarterly dividend 9% to 88c per share - Avery Dennison Corporation announced that its board of directors has increased the company's quarterly dividend. The board declared a quarterly dividend of 88c per share, representing an increase of approximately 9% over the previous dividend rate. The dividend for the second quarter is payable on June 20 to shareholders of record as of June 5.

12:50 EDT Southwest still expects similar cost pressures throughout year - Says headcount will be down again in 2025. Says planning more voluntary leave programs. Says "aggressively" looking at ways to reduce costs and handle inflationary pressures.

12:43 EDT Boeing rating outlook revised to negative by S&P Global - S&P Global Ratings lowered the rating outlook for Boeing to negative from stable and affirmed it "BBB-" long- and "A-3" short-term issuer credit ratings. The outlook was revised to negative primarily to reflect the increased potential for Boeing to face further delays in the expected recovery of its cash flow and credit ratios to levels consistent with its rating, mainly related to its commercial aircraft production and deliveries, S&P said in a statement.

12:37 EDT Joby Aviation partners with Abu Dhabi to establish electric air taxi ecosystem - Joby Aviation announced it has signed a multilateral Memorandum of Understanding with the Department of Municipalities and Transport - Abu Dhabi, the Abu Dhabi Department of Economic Development and the Department of Culture and Tourism - Abu Dhabi that lays the groundwork for Joby to establish and scale air taxi services in Abu Dhabi and beyond. The MoU, signed at the DRIFTx international thought-leadership and exhibition platform in Abu Dhabi, demonstrates the breadth of support available to Joby as part of their participation in the Smart and Autonomous Vehicles Industry cluster and builds on Joby's existing commitments to the UAE, including the exclusive right to operate air taxi services in Dubai, which the company expects to start as early as next year, Joby said. The agreement also unlocks the potential for inter-emirate air taxi services, for example between Abu Dhabi and Dubai. JoeBen Bevirt, founder and CEO, Joby Aviation, said: "Today's agreement demonstrates the incredible momentum behind the adoption of clean flight across the UAE. We're looking forward to delivering a fantastic experience for our future customers in Abu Dhabi and we're excited to be unlocking the potential for zero-emissions flight between Abu Dhabi and Dubai. We're grateful for the support and collaboration of our governmental partners and the entire ecosystem in Abu Dhabi and we remain deeply impressed by their commitment to building out a world-class aviation ecosystem in the Emirate."

12:30 EDT Airbus to increase A350 production rate to 12 per month in 2028 - The company said, "The A220 ramp-up continues towards a monthly production rate of 14 aircraft in 2026, with a focus on the programme's industrial maturity and financial performance. On the A320 Family programme, the Company is making progress towards the rate of 75 aircraft per month in 2026. Entry-into-service of the A321XLR continues to be expected in Q3 2024. On widebody aircraft, the Company has decided to increase the production rate for the A350 to 12 aircraft a month in 2028 and continues to target rate 4 for the A330 in 2024."

12:00 EDT Live Oak Bancshares falls -14.8% - Live Oak Bancshares is down -14.8%, or -$5.89 to $33.98.

12:00 EDT Orion Group falls -17.7% - Orion Group is down -17.7%, or -$1.41 to $6.55.

12:00 EDT Sonic Automotive rises 10.5% - Sonic Automotive is up 10.5%, or $5.38 to $56.49.

11:56 EDT Park Aerospace CFO Matt Farabaugh to retire - Park Aerospace announced that the Company's Board of Directors has elected Chris Goldner as Vice President-Finance of the Company. Park also announced that P. Matthew Farabaugh, the Company's long time Senior Vice President and CFO, plans to retire from the Company at the end of May 2024. Matt joined the Company in October of 2007 and has served as the Company's CFO since April 2012. Matt has agreed to serve as a consultant to the Company after his retirement. Chris started with Park on March 4, 2024 and has been working with Matt and Park's accounting staff for the last two months to facilitate the transition. Upon Matt's retirement, Chris will report to Brian Shore, the Company's Chairman and CEO, and Chris will serve as the Company's principal financial officer. Chris served as Corporate Controller and Interim CFO of Spruce Power Holdings Corporation, a public company located in Boston, Massachusetts, from 2021 through 2023.

11:03 EDT Amazon Prime Video to become home of national Monday night NHL games in Canada - Amazon (AMZN), Rogers Communications (RCI), and the National Hockey League announced a "milestone two-year agreement" in Canada to bring hockey fans Monday night NHL hockey exclusively on Prime Video. "Prime Monday Night Hockey will stream all national regular season Monday night NHL games in English for the 2024/25 and 2025/26 NHL seasons. The deal is the NHL's first exclusive national broadcast package with a digital-only streaming service in Canada. The Prime Monday Night Hockey package, produced by Prime Video, will feature a new broadcast team offering in-depth analysis and play-by-play coverage, and stream live exclusively to Prime members in Canada," the companies stated.

10:34 EDT Honda to establish 'comprehensive electric vehicle value chain' in Ontario - Honda Motor announced that it plans to build a comprehensive EV value chain in Canada with an approximate investment of C$15B, or U.S. $11B, including investment by joint venture partners, to strengthen its EV supply system and capability to prepare for a future increase in EV demand in North America. "Honda has begun evaluating the requirements to build an innovative and environmentally responsible Honda EV plant and a stand-alone Honda EV battery plant in Alliston, Ontario. The proposed Honda EV value chain will also include a cathode active material and precursor processing plant through a joint venture partnership with POSCO Future M Co., Ltd. and a separator plant through a joint venture partnership with Asahi Kasei Corporation, with announcements to follow in their respective Ontario communities. Honda expects that electric vehicle production will begin in 2028. Once fully operational, the EV plant will have a production capacity of 240,000 EVs per year and the EV battery plant will have a capacity of 36 GWh per year. In addition to securing the current employment level of 4,200 associates at its two existing manufacturing facilities in Ontario, Honda estimates it will add a minimum of 1,000 new associates for the EV and EV battery manufacturing facilities. The investment in the new facilities will also create significant spinoff jobs across all sites, including in the construction sector. Honda has begun the process of evaluating the scope of its investment and completing negotiations with its joint venture partners. This work is expected to be finalized during the next six months and more details will be shared at that time. To support this project, Honda is collaborating with the governments of Canada and Ontario to drive innovation in low-emissions manufacturing by accessing performance-based initiatives available through the federal government's new Investment Tax Credits and provincial direct and indirect incentives," the company stated. Reference Link

10:09 EDT T-Mobile, EQT announce joint venture to acquire Lumos - T-Mobile and EQT have entered into a joint venture with EQT's Infrastructure VI fund that will acquire fiber-to-the-home platform Lumos from EQT's predecessor fund EQT Infrastructure III. The JV will bring T-Mobile's retail, marketing, brand and customer experience strengths together with EQT's fiber infrastructure investment expertise. Together they will acquire Lumos' scalable fiber network build capabilities to deliver best-in-class high-speed fiber internet connectivity to customers across the U.S. without access to fiber today. After the transaction closes, Lumos, which currently reaches 320,000 households over 7,500 route miles with fiber optic internet and home wi-fi service in the Mid-Atlantic, will transition to a wholesale model with T-Mobile as the anchor tenant owning customer relationships and leveraging its brand to attract new subscribers. The JV will focus on market identification and selection, network engineering and design, network deployment, and customer installation. The transaction is expected to close in late 2024 or early 2025, subject to customary closing conditions and regulatory approvals. At closing, T-Mobile is expected to invest approximately $950 million in the JV to acquire a 50% equity stake and all existing fiber customers, with the funds invested by T-Mobile being used by Lumos for future fiber builds. The next capital contribution by T-Mobile out of an additional commitment of approximately $500 million is anticipated between 2027 and 2028. These combined investments are expected to allow Lumos to reach 3.5 million homes passed by the end of 2028. T-Mobile continues to expect to complete its remaining authorization for share repurchases and dividends in 2024. With this transaction, EQT Infrastructure VI is expected to be 35-40% percent invested based on target fund size and subject to customary regulatory approvals.

10:04 EDT Tiziana Life Sciences reports three-month neuroimaging scores in MS patients - Tiziana Life Sciences announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis. White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain. Tarun Singhal, MBBS, M.D., Director of PET Imaging Program in Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System, and Associate Professor of Neurology at Harvard Medical School, stated, "Last week at the American Academy of Neurology annual meeting, we presented, for the first time, quantitative PBR06-PET data showing the dampening of microglial activation, an indicator of brain inflammation, in patients with non-active Secondary Progressive Multiple Sclerosis receiving intranasal foralumab. These data came from the open-label intermediate-sized patient population Expanded Access program. We calculated White Matter Z-scores to measure the effect of intranasal foralumab on microglial activation at baseline and then after foralumab treatment for three months. We saw reductions of 28% to 48%, indicating improvement in 5 out of 6 patients, and a 36% median reduction in White Matter Z-scores compared to baseline. A peer-reviewed journal has published our recent work with newer PBR06-PET quantitation approaches."

10:00 EDT Harley-Davidson falls -15.7% - Harley-Davidson is down -15.7%, or -$6.18 to $33.26.

10:00 EDT TransUnion rises 7.9% - TransUnion is up 7.9%, or $5.46 to $74.14.

10:00 EDT Sonic Automotive rises 11.4% - Sonic Automotive is up 11.4%, or $5.80 to $56.92.

09:56 EDT Northrop Grumman says 'no concerns about our portfolio' - Says International demand "strongest in a long time." Sees significant opportunities in International market.

09:49 EDT BMWED-IBT says change in leadership 'needed' at Norfolk Southern - The Brotherhood of Maintenance of Way Employes Division of the International Brotherhood of Teamsters announced that it has determined a change in leadership at Norfolk Southern Corporation is necessary. Tony Cardwell, President of BMWED-IBT, commented: "The BMWED-IBT, after more than a year of non-committal hedging on reasonable, needed changes and untenable shakiness in management at Norfolk Southern, has determined that a change in leadership is needed for the freight rail carrier and its employees. Following yesterday's earnings call and a reasonably constructive meeting with a potential new leadership team, our Brotherhood has determined that a change at the top would be the best course of action for BMWED-IBT members. For many months since East Palestine, the BMWED has not been able to get assurances from the current leadership to implement needed policy and procedural changes to prevent such tragedies from reoccurring. At this juncture, seeing no path forward, we see no reason to support the current administration at Norfolk Southern."

09:47 EDT Live Oak Bancshares falls -9.6% - Live Oak Bancshares is down -9.6%, or -$3.83 to $36.04.

09:47 EDT Teck Resources rises 7.9% - Teck Resources is up 7.9%, or $3.57 to $49.01.

09:47 EDT TransUnion rises 9.8% - TransUnion is up 9.8%, or $6.73 to $75.41.

09:44 EDT Acrivon Therapeutics Inc trading resumes

09:40 EDT ATN International trading resumes

09:34 EDT Acrivon Therapeutics Inc trading halted, volatility trading pause

09:31 EDT Mainz Biomed reports topline results from pooled study of mRNA biomarkers - Mainz Biomed announced topline results from a pooled clinical study which included new patients and subjects from Mainz Biomed's ColoFuture and eAArly DETECT clinical trials evaluating the potential to integrate its portfolio of proprietary novel gene expression biomarkers into a next generation version of the Company's colorectal cancer screening tool. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, which is best-in-class and compare favorably to existing commercial products. The pooled results include 690 evaluable subjects across 21 sites in the U.S. and 9 sites in Europe. The two cohorts included patients that provided a stool sample before undergoing a colonoscopy to either screen for CRC. to follow up on a positive non-invasive test, imaging or symptoms, or if a subject was already identified as having colorectal cancer but before any treatment had been administered. Following colonoscopy and any applicable histopathology, subjects were classified into groups: CRC, advanced adenoma, non-advanced adenoma, no findings, or non-colorectal cancer. Each subject outcome was compared to the results from the next generation test incorporating the novel mRNA biomarkers and FIT. The Company plans to publish results of this study at a major medical conference during the second quarter of 2024.

09:22 EDT Northrop Grumman expects 'gradual ramp' of sales through 2024 - Says "pleased with cash performance" in Q1. Expects strong cash generation in Q2. Says "committed" to "strong and growing dividend." Remains "upbeat" on long-term prospects.

09:19 EDT American says will talk more on capital allocation after getting to debt target - American CEO Robert Isom, asked about the company's debt reduction goal and plans to consider capital returns, replied: "Consistent with what we've been saying, we are focused on the debt reduction target. We're looking forward to talking about other opportunities beyond that point. But right now, we want to get through our $15B, hit that number, and then we will talk more about capital allocation as we get beyond 2025."

09:17 EDT Aclarion's Nociscan solution to be utilized in LIFEHAB trial - Aclarion announced that the Nociscan solution will be utilized in the upcoming LIFEHAB Trial in Norway. The randomized controlled trial studying 202 patients with low back pain greater than 1 year in duration will compare treatment outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation. The Company believes the LIFEHAB trial combined with other compelling evidence, marks an important step toward achieving successful reimbursement in a single-payer national health insurance system like Norway's, which was adopted in 1966.

09:15 EDT Coveo Solutions joins the MACH Alliance - Coveo announced that it has joined the MACH Alliance, the group of independent tech companies dedicated to advocating for open, best-of-breed technology ecosystems. Its inclusion in the MACH Alliance recognizes Coveo's strength in composable AI technology, meeting the MACH standard of modern technology: microservices based, API-first, cloud-native SaaS, and headless.

09:12 EDT Innodata releases open-source LLM Evaluation Toolkit - Innodata has released an open-source LLM Evaluation Toolkit, together with a repository of 14 semi-synthetic and human-crafted evaluation datasets, that enterprises can utilize for evaluating the safety of their Large Language Models in the context of enterprise tasks. Using the toolkit and the datasets, data scientists can automatically test the safety of underlying LLMs across multiple harm categories simultaneously. By identifying the precise input conditions that generate problematic outputs, developers can understand how their AI systems respond to a variety of prompts and can identify remedial fine-tuning required to align the systems to the desired outcomes. Innodata encourages enterprise LLM developers to begin utilizing the toolkit and the published data sets as-is. Innodata expects a commercial version of the toolkit and more extensive, continually-updated benchmarking datasets to become available later this year.

09:11 EDT Northrop Grumman says demand for products 'continues to be robust' - Says strong global defense budget outlook; broad portfolio well aligned to customer priorities; robust long-term cash flow outlook. Expects greater than $2B in share repurchases in 2024. Says "laser focused" on performance, driving cost efficiencies in the business. Comments taken from Q1 earnings conference call.

09:11 EDT M2i Global partners with Komoda Capital - M2i Global announced its execution of a strategic partnership with Komodo Capital, a mergers and acquisition firm with significant relationships in Australia. The goal of the strategic partnership is for Komodo Capital to utilize its relationships, which span many years and range across more than 25 mineral asset and mining companies in Australia, to provide access of various critical minerals to M2i Global for the ultimate supply to the U.S. government and U.S. free trade partners.

09:10 EDT Diana Shipping announces time charter contract for m/v DSI Phoenix - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Bulk Trading SA, for one of its Ultramax dry bulk vessels, the m/v DSI Phoenix. The gross charter rate is US$16,500 per day, minus a 5% commission paid to third parties, for a period until minimum August 1, 2025 up to maximum September 30, 2025. The charter is expected to commence on May 8, 2024. The m/v DSI Phoenix is currently chartered, as previously announced, to ASL Bulk Marine Limited, at a gross charter rate of US$13,250 per day, minus a 5.00% commission paid to third parties. The "DSI Phoenix" is a 60,456 dwt Ultramax dry bulk vessel built in 2017.

09:09 EDT Verizon announces new benefits to Home Device Protection service - Beginning April 25, customers with Verizon Home Device Protect will gain access to new benefits and services at no additional cost, including: Expanded Protection; Second Residence Coverage; Complete Tech Care; Benefits for Verizon Home Internet customers.

09:08 EDT BioCardia completes enrollment of CardiAMP cell therapy trial - BioCardia announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial.

09:06 EDT Calavo Growers provides update to shareholders - Calavo Growers yesterday at its Annual Meeting of Shareholders said in a business update that: The Company has made significant progress toward completing the proposed sale of the Fresh Cut business and related real property and expects to close in May 2024; As previously shared, the expected uses of sale proceeds would include paying down debt and returning cash to shareholders; The Company's internal investigation into potential Foreign Corrupt Practices Act violations in Mexico is winding down and the Company will share more with investors when it is able to do so

09:05 EDT Safe & Green entered agreement to manufacuter four container based centers - Safe & Green Holdings announced that Safe and Green Holdings has entered into an agreement to manufacture four container based electrical distribution centers as part of a multi-unit order for a client serving the big box retailer market. Paul Galvin, Chairperson and CEO of Safe and Green Holdings stated, "We are pleased that we have entered into this agreement to produce the first four units of what we anticipate will be a 20-unit order for 2024. Over the years, Safe and Green has manufactured over a hundred of these modular electrical distribution center units, and we are excited to be manufacturing them again. The versatility of these units allows for electrical distribution wherever and whenever it's needed, once again highlighting one of the key advantages of modular construction."

09:03 EDT Northrop Grumman provides 2024 sector guidance - For 2024 sees: Aeronautics Systems sales mid $11B, OM rate mid 9%; Defense Systems sales ~ $6B, OM rate low to mid 12%; Missions Systems sales low to mid $11B, OM rate high 14%; Space Systems sales low to mid $14B, OM rate ~9%; Eliminations ~($2.3B), OM rate high 13%. Prior view: Aeronautics Systems sales low $11B, OM rate mid 9%; Defense Systems sales ~ $6B, OM rate low 12%; Missions Systems sales low to mid $11B, OM rate ~ 15%; Space Systems sales mid to high $14B, OM rate ~9%; Eliminations ~($2.3B), OM rate high 13%. Comments taken from investor presentation slides. Comments taken from investor presentation slides.

09:02 EDT Precision Optics announces receipt of $1.26M follow on production order - Precision Optics Corporation announced the receipt of a follow-on production order totaling approximately $1.25 million from a major U.S. defense contractor, to meet continued demand for a highly complex optical assembly developed by Precision Optics. Approximately half of the order is expected to be delivered in the next 6 months, with the remainder to be delivered over the following 6 to 12 months. "We are excited to have received yet another sizeable follow-on production order from this leading U.S. defense contractor," commented Dr. Joe Forkey, CEO of Precision Optics. "This order comes immediately on the heels of us completing a 15-month production order for the same unique assembly, allowing our team to maintain a high level of continuity with the program and realize manufacturing efficiencies. We look forward to a continued strong relationship with this customer for years to come."

09:01 EDT Conduent implements I-64 Hampton Roads Express Lanes tolling for VDOT - Conduent Transportatio announced the implementation of an Express Lanes tolling system in Virginia. The system, which went live March 17 on a segment of the I-64 Hampton Roads Express Lanes, was designed by Conduent as part of a 2021 contract from the Virginia Department of Transportation VDOT . Conduent will operate and maintain an innovative and completely overhead vehicle classification system, a traffic responsive dynamic pricing system and an automated license plate recognition system, as well as conduct license plate image reviews for VDOT. These technologies and services are designed to help improve traffic flow and relieve congestion for motorists and passengers. To enable dynamic pricing, VDOT will use data analytics to determine toll rates based on the volume of traffic during different times of the day, helping reduce overall travel times and enhance predictability and mobility choices for motorists. The lanes remain free for vehicles with two or more occupants using a required E-ZPass Flex transponder.

08:55 EDT American Resources' ReElement receives certificate of occupancy for Indiana site - American Resources Corporation's ReElement Technologies has received its initial certificate of occupancy for its Marion, Indiana Advanced Technology Center supersite, which will be a first mover in reducing the chokehold that China has on the refining for critical and rare earth elements. ReElement is focused on building out phase 1 operations with the ability and goal of significantly expanding the Marion site beyond the initial production capacity over time. Phase 1 production capacity represents approximately $142 million in revenue potential based on current market prices of rare earth oxides and lithium carbonate production. The ReElement Technologies Marion Refining Campus will provide for: 42 acres with ample areas for operations and future development for both ReElement Technologies and its key industry partners; 425,000 square feet of existing production facility space, office, laboratories, and support structures; 250,000 square feet of additional foundation-ready space to expand production facilities or structures for further growth; The production of rare earth elements with a targeted initial capacity to produce 1,000 metric tons per year of ultra-pure rare earth oxides sourced from virgin ores and recycled feedstocks, such as magnets found in high-efficiency motors, electric vehicles, wind turbines, power tools, and hard drives, and establishing the largest such producer of heavy rare earth elements outside of China; The production of critical battery materials with an initial refining capacity of 50 metric tons per day of lithium-ion battery input material sourced from end-of-life batteries and manufacturing waste, with the ability to process a wide range of lithium-ion battery chemistries including Lithium Iron Phosphate and Nickle Manganese Cobalt; An onsite fully integrated domestic solution of the battery and magnet supply chains: The campus is being designed to drive collaboration with battery and magnet industry partners by creating co-located partnerships within the electrified value chain; reducing costs, maximizing productivity, and significantly reducing the carbon footprint of products produced; Rail loadout onsite along with 37 truck bays for enhanced transportation logistics, including access to major highways and interstate travel, with a central location to many potential customers within the automobile, battery and magnet industries within the U.S. battery belt; and Exceptional community support for ReElement Technologies, along with access to several important educational institutions, such as Indiana Wesleyan University, Ivy Tech Community College, Taylor University and Purdue University which can provide skilled personnel to ReElement Technologies' expanding workforce. The Marion Advanced Technology Campus will scale up to an initially targeted production capacity of 5,000 metric tons of ultra-pure lithium hydroxide or carbonate per year, and 1,000 metric tons per year of rare earth oxides, with the ability to strategically and efficiently expand production capacity by adding modular production capacity as the market matures.

08:47 EDT SKYX Platforms announces new collaboration with Chinese lighting supplier - SKYX Platforms announces a new collaboration with a Chinese lighting supplier and manufacturer Ruee Appliances for the US, Chinese, and European Markets. The collaboration provides SKYX substantial backing in several areas including financial, mass production manufacturing capabilities, and distribution to global markets. The collaboration agreement introduces operational and logistical efficiencies and is expected to substantially enhance gross margins on SKYX's product sales. Rani Kohen, Founder and Executive Chairman of SKYX, said, "This partnership marks a significant milestone that will assist us to expand our technology and products to global markets, while enhancing our financial foundation. Aligning with industry leaders who support our vision for growth and innovation in smart home and lighting sectors is key to our growth strategy. We anticipate announcing additional high impact collaborations as we advance our next-generation technology solutions."

08:45 EDT American CFO says aircraft delivery delays not having same impact as on peers - American CFO Devon May said on the company's Q1 call: "Aircraft delivery delays are impacting the entire industry, but they are not having the same impact on American as other carriers since we are not as dependent on new aircraft deliveries as most of our peers. We have modest aircraft CapEx requirements this decade due to our previous refleeting efforts. We now expect our 2024 aircraft CapEx to be approximately $2.2B, our total CapEx to be approximately $3.1B. We continue to expect aircraft CapEx to be approximately $3B to $3.5B per year from 2025 through 2030."

08:44 EDT Altius Minerals increases ownership of Orogen Royalties to 18.15% - Orogen Royalties announces Altius Minerals Corporation has increased its ownership in Orogen. Altius Resources Inc., a wholly owned subsidiary of Altius, has acquired 7,115,545 common shares of Orogen through the exercise of 7,115,545 common share purchase warrants at $0.4017. The warrants were acquired through a private placement completed in April 2019. The total amount received for the warrant exercise is $2,858,314. Altius now holds a total of 36,430,561 common shares, or 18.15% of the issued and outstanding common shares of the Company and 17.18% on a fully diluted basis.

08:42 EDT Star Equity's KBS Builders closes $4M revolving line of credit - Star Equity Holdings announced that its KBS Builders business unit has closed a $4 million revolving line of credit with KeyBank National Association. KBS intends to use the LOC to meet its working capital requirements and execute its business plan. The closing of this LOC provides both KBS and Star with financial flexibility to focus on their respective growth initiatives. The LOC has an April 30, 2025 maturity date, which can be extended based on fulfillment of certain terms and conditions. Borrowings under the LOC will bear an interest rate of SOFR plus an applicable margin of 3.00%.

08:41 EDT Mangoceuticals acquires a global patent portfolio for preventative care - Mangoceuticals announces that it has acquired a global patent portfolio for a pioneering oral solution and application aimed to combat and prevent a spectrum of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus, HPV, from Intramont Technologies pursuant to a Patent Purchase Agreement, PPA. Jacob Cohen, Co-Founder and CEO of MangoRx commented, "We are thrilled to integrate this groundbreaking solution into our current portfolio of products, as this further signifies our entrance into non-prescription, or non-Rx, based products, which can be sold both via direct-to-consumer online or in retail locations. This acquisition aligns perfectly with our mission to enhance well-being through innovative health solutions. Through working to commercialize this technology, we aim to unlock significant value for our shareholders while advancing global health and addressing significant market needs."

08:40 EDT Navitas highlights EV high-speed hybrid power semiconductor advances - Navitas Semiconductor announced its participation in forthcoming China Electronic Hotspot Solutions Innovation Summit in Shenzhen on April 27th. The summit gathers key players in power semiconductors and associated customer design teams for innovations in EV such as 800 V supercharging, battery management, intelligent connected vehicle electronics, and high-power digital power supplies. 2024 EV OEM attendees include experts from Voyah and Dongfeng. Jacky Xiao, Navitas' Technical Marketing Manager, will deliver a keynote titled "High-Frequency On-Board Charger Solutions Based on Hybrid Design of SiC and GaN", to introduce how Navitas can create more efficient, smaller and lighter on-board charging for EVs. Without compromise, customers can select Navitas' optimal, feature-rich GaN and SiC power devices in robust, thermally-enhanced TOLL and TOLT packaging, to create hybrid powertrain solutions that deliver faster charging, longer range and lower systems costs. Navitas' GaNFast power ICs integrate GaN power and drive with control, sensing, and protection to enable faster charging, higher power density, greater energy savings and system cost reduction. New 'Gen-3 Fast' GeneSiC MOSFETs have up to 50% improved performance vs. other SiC devices. Summit exhibition attendees can explore the latest in EV-optimized GaNFast and GeneSiC products and complete EV system hardware solutions and learn how to accelerate their leading-edge projects.

08:39 EDT Vistagen says PH15 shows statistically significant improvement in reaction time - Vistagen announced results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants. The previously unreported randomized, double-blind, placebo-controlled, crossover Phase 2A pilot study of PH15 was designed to explore the efficacy, safety, and tolerability of intranasal administration of PH15 on psychomotor performance as measured by reaction time in sleep-deprived participants. Ten participants were randomly administered PH15, placebo, or caffeine in sequential sleep deprivation study sessions spaced one week apart. During each sleep deprivation session, participants received blinded treatments before the start of each of four testing periods, at 6:00 p.m., 9:00 p.m., midnight, and 3:00 a.m. The participants' reaction times to both isochronous and stochastic "flash" light stimuli were computer-measured during each testing period as participants responded to the luminous stimuli. During both isochronous and stochastic reaction time tests, administration of 1.6 microgram PH15 nasal spray induced a significantly faster mean reaction time compared to placebo nasal spray across all time points. PH15 also demonstrated a statistically significant improvement in reaction time compared to oral caffeine for both reaction time tests during the testing periods at midnight and 3:00 a.m. when subjects were most fatigued. PH15 was well-tolerated with no serious adverse events reported. The adverse event profiles of PH15 and placebo were comparable, with brief nasal itching in one PH15-dosed participant and three placebo-dosed subjects. Participants on oral caffeine, however, experienced palpitations, euphoria, dry mouth, stomachache, and polyuria. This previously unreported Phase 2A pilot study of PH15 was sponsored by Pherin Pharmaceuticals, now a wholly owned subsidiary of Vistagen, and conducted at the National Institute of Psychiatry, Sleep Disorders Clinic in Mexico City, Mexico in 2011. Vistagen gained access to the results of this study in connection with its acquisition of Pherin in February 2023. The late Jose Maria Calvo, MD, formerly Associate Professor, National Institute of Psychiatry in Mexico City, served as the Principal Investigator of the study.

08:38 EDT La Rosa Holdings acquires tenth real estate brokerage franchisee - La Rosa Holdings announced that it has completed an acquisition transaction and now holds a 51% interest in the Company's franchisee - La Rosa Realty Lakeland, located in Lakeland, Florida with a separate branch in Winter Haven, Florida. Prestige generated revenue of $4.7 million and had positive net income in 2023. The franchisee provides residential and commercial real estate brokerage services. It also provides coaching and support services to agents on a fee basis. Joe La Rosa, CEO of the Company, commented, "With 162 agents, Prestige has solidified its position as number two for agent count and number three for real estate sales in Polk County, Florida in 2023. This latest acquisition represents yet another milestone for the Company, aligning with our roll-up strategy focused on acquiring profitable franchisees and further solidifying our market position while creating value for shareholders. This acquisition is expected not to only increase our revenue but also, as we seamlessly integrate this and prior acquisitions, we anticipate gaining the rewards of enhanced operating efficiencies and economies of scale. We believe that these advantages will further strengthen our competitive position in the market and fuel our journey towards sustainable growth. With this strategic expansion strategy firmly in place, we believe we are positioned for significant advancement and remain on track to achieve our goal of reaching an annualized revenue run rate of $100 million by the end of 2024. Furthermore, we anticipate attaining profitability in 2025."

08:37 EDT Gaia announces return of 'The Journey of Remembering' series - Gaia announced that the second season of its highly-anticipated original series The Journey of Remembering is now available exclusively on Gaia. The premiere of this eight-episode series includes the first three episodes, with new episodes released each Monday at 2:00 a.m. MT. In season two of this exclusive Gaia Original docuseries, Matias De Stefano guides 45 initiates on a challenging journey he took himself years ago. Together, the group travels to stone circles and sacred sites throughout Great Britain, retracing an ancient path of initiation. Along the way, they practice Druidic ceremonies led by wise "Merlins," learning how to work with powerful Earth energies and heal buried memories and emotions that have been holding them back.

08:36 EDT Sabre distribution network selected by National Travel agency - Sabre announced a new multi-year agreement with National Travel, a global travel agency. The new agreement gives National Travel, which books a considerable amount of government travel, access to the travel content in the Sabre travel marketplace. National Travel's migration to Sabre is underway with an anticipated launch of the program later this quarter.

08:35 EDT AMMO acquires tooling manufacturer, terms not disclosed - AMMO has acquired a tooling manufacturer that provides key resources toward the production of ammunition in its Manitowoc, Wisc. factory. The Company expects that this acquisition will result in both streamlined operation of the factory and an annualized cost savings of over $1 million.

08:28 EDT Microchip launches MXT2952TD 2.0 family of secure touchscreen controllers - Microchip Technology has launched the MXT2952TD 2.0 family of secure touchscreen controllers. The company said, 'Typical touch-enabled human machine interface and radio frequency identification combination-based payment systems are vulnerable to hacking attacks via malicious software updates or man-in-the-middle attacks when a user enters their personal identification number on the touchscreen. Physical mesh barriers and sensors are often used around these integrated circuits for protection from hacking. Constant reflashing of software and device resets are used to help safeguard software integrity. The MXT2952TD 2.0 family is designed to encrypt touch data and cryptographically authenticate software updates to minimize risk and meet PCI certification compliance standards. When the RFID reader IC and the touchscreen controller are on different printed circuit boards, it is especially difficult and expensive to build physical barriers for hack protection. Embedded firmware on the MXT2952TD 2.0 provides a more easily implemented solution for EV charger manufacturers to remain compliant with security regulations and avoid the cost of adding a second, expensive touchscreen payment module to the charger."

08:26 EDT Imperial Metals reports Q1 copper production 12.353M pounds - Imperial Metals Corporation reports quarterly copper and gold production from Mount Polley and Red Chris mines. Imperial's production was 12.353 million pounds copper and 12,861 ounces gold, with 7.355 million pounds copper and 10,009 ounces gold coming from Mount Polley and 4.998 million pounds copper and 2,852 ounces gold from its 30% share of Red Chris mine production. Mount Polley metal production for the first quarter of 2024 was 7.355 million pounds copper and 10,009 ounces gold, compared to 6.678 million pounds copper and 9,980 ounces gold produced during the first quarter of 2023.

08:25 EDT Northrop Grumman backs FY24 CapEx view about $1.8B - Backs FY24 free cash flow view $2.25B-$2.65B.

08:23 EDT CCSC Technology appoints Jung Yi Chiu as Chief Strategy Officer - CCSC Technology International announced that the Company has appointed Jung Yi Chiu as the Chief Strategy Officer of the Company, effective May 1, 2024. Chiu joined the Company in August 2020 as the Develop Strategy Officer.

08:19 EDT Marti Technologies announces three-month extension to share repurchase program - Marti Technologies announced an amendment to its share repurchase program. The company's board authorized a three-month extension to its original six-month share repurchase program under which the company may repurchase up to $2.5M of its outstanding Class A ordinary shares, which was originally initiated on January 10. In addition, the board set a ceiling price of $3.30 per share for the share repurchases, giving the company the ability to perform share repurchases up to a maximum share price of $3.30. As of market close on April 24, the company's share price was $1.53. The amended repurchase program is effective immediately and is valid until October 9.

08:18 EDT Aligos Therapeutics mourns passing of advisor Stephen Harrison - Aligos Therapeutics wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col FAASLD, who served as a trusted advisor and the Principal Investigator for the Company's ongoing Phase 2a HERALD study in metabolic dysfunction-associated steatohepatitis subjects. Thanks to Dr. Harrison's expertise in designing and implementing HERALD, the study is continuing to enroll, dose subjects, and remains on track for the anticipated topline data readout in Q4 2024.

08:18 EDT Candel Therapeutics to present on CAN-3110, CAN-2409 at ASCO meeting - Candel Therapeutics announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma. The presentation will focus on patients recruited in cohort C, treated with multiple injections of CAN-3110, demonstrating that this approach is both feasible and well tolerated. The second presentation will show topline overall survival data from the phase 2 clinical trial of CAN-2409 plus valacyclovir, in combination with continued immune checkpoint inhibitor treatment in patients with non-resectable, stage III/IV non-small cell lung cancer who have an inadequate response to front line anti-PD(L)1 therapy.

08:16 EDT Sportradar appoints Felenstein as Chief Financial Officer - Sportradar Group (SRAD) announced that Craig Felenstein has been named Chief Financial Officer of the Company, effective June 1, 2024. Felenstein joins the Company from Lindblad Expeditions (LIND) where he most recently served as Chief Financial Officer. He will report directly to Sportradar Chief Executive Officer Carsten Koerl. Most recently, Felenstein served as Chief Financial Officer at Lindblad Expeditions.

08:15 EDT Byrna Technologies raises production target to 18,000 launchers per month - Byrna's production ramp-up began with a scale to 12,500 units in January 2024, reaching 14,400 by March, and is projected to hit 16,300 in April. This initiative aims not only to satisfy the rising demand but also to ensure ample stock availability for the holiday season and beyond. CEO John Brasseur said, "Our planned increase in production capacity to 18,000 units per month by May 2024 will allow us to meet run-rate demand and ensure we are well-stocked for the upcoming holiday shopping season."

08:14 EDT Byrna Technologies appoints John Brasseur as COO - Byrna Technologies announced the promotion of John Brasseur to COO and provided an update on its production plans. John Brasseur, who joined Byrna in July of last year as Vice President of New Product Development, has been promoted to COO, where he will oversee Supply Chain, Global Production, Engineering, and New Product Development.

08:13 EDT American Oncology Network launches American Oncology Cares Foundation - American Oncology Network launched its American Oncology Cares Foundation through its partner practices Hematology Oncology of Indiana in Indianapolis and Hope Cancer Care of Nevada in Las Vegas. Non-medical expenses such as rent or mortgage, utilities, transportation costs and food qualify under the Foundation's essential living expenses requirement. Grant recipients are eligible to receive up to $750 per calendar year. Fifty-one percent of cancer patients have reported going into medical debt because of care and treatment costs and more than 70% responded that they are worried about affording their care, according to a survey by the American Cancer Society.

08:11 EDT MediWound to present data from EscharEx Phase II studies - MediWound announced that recent clinical data from EscharEx Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association, the Wound Healing Society, and the Symposium on Advanced Wound Care. The oral presentations on EscharEx will include: Comparative data of EscharEx vs. SANTYL that demonstrate EscharEx's superiority over the current leading enzymatic debridement agent; New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing; These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care. Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024. "We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL(R), the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound. "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."

08:11 EDT Archer in 'multi-hundred-million' deal for commercialization of air taxis in UAE - Archer Aviation announced the signing of a framework agreement in Abu Dhabi today at the DRIFTx mobility event, held at the Yas Marina Circuit showcasing the latest in advanced urban mobility, driving discussions, collaboration, and innovation across the sector. This agreement covers multi-hundred-million dollar investments to accelerate Archer's planned commercial air taxi operations in the UAE, slated to launch as soon as next year, including in-country manufacturing, operations and training across the region. This comprehensive agreement positions Abu Dhabi as one of the world's leaders in promoting urban air mobility, with plans to commence air taxi operations with Archer's Midnight aircraft as soon as next year...Key components of Archer's collaboration with ADIO include vertiport construction, operational enablement for air taxi operations in the UAE, and in-country manufacturing of Archer's Midnight aircraft. Under the agreement, ADIO will also ensure local workforce development programmes for Emirati talent and facilitate the establishment of Archer's international headquarters and Centre of Excellence in Abu Dhabi. "This substantial agreement with Abu Dhabi is a pivotal moment for Archer's commercialisation efforts across the Emirates, as it provides the catalyst to accelerate the launch of our electric air taxi service in the UAE as soon as late 2025. The agreement underscores Abu Dhabi's strong commitment to Archer and conviction to become a global hub for urban air mobility. With Abu Dhabi's support, we are poised to continue leading the transformation of urban transportation in the Emirate and across the globe," said Archer founder and CEO, Adam Goldstein.

08:09 EDT SuperCom receives over $5.0M in new orders from European governments - SuperCom received new orders by European governments. The orders are valued at over $5.0M and are anticipated to be delivered in the next three months. SuperCom's PureSecurity Suite is an end-to-end electronic monitoring solution with GPS tracking, secured communication, monitoring technologies, and a software platform providing real-time tracking and Monitoring.

08:07 EDT Bitcoin Depot announces strategic investment from Sopris Capital - Bitcoin Depot announced a strategic investment from Sopris Capital, a 20-year-old multi-strategy investment firm. As part of the investment, Sopris Capital has purchased 2,906,976 Class A common shares and is now one of the Company's largest independent shareholders. "We are thrilled to own part of a growing, market-leading business at such a compelling valuation. We look forward to collaborating with Bitcoin Depot as they pursue their numerous growth initiatives," said Andy Paul, Founder and CEO of Sopris Capital.

08:06 EDT Tricon Residential receives Investment Canada Act approval for take private deal - Tricon Residential announced receipt of Investment Canada Act approval in connection with the previously announced statutory plan of arrangement under the Business Corporations Act pursuant to which Blackstone Real Estate Partners X, together with Blackstone Real Estate Income Trust, will acquire all of the outstanding common shares of Tricon for $11.25 per common share in cash.

08:04 EDT AbbVie reports 'positive' results from LEVEL UP study - AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or when use of those therapies was inadvisable. In the LEVEL UP study, upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index and a Worst Pruritus Numerical Rating Scale of 0 or 1 at Week 16.

07:55 EDT FSD Pharma provides update from Celly Nu's partnership with Six+One - FSD Pharma provides an update by way of a news release issued by Celly Nutrition Corp, and its launching of unbuzzd. On April 25, 2024, Celly Nu announced a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City as follows: "Celly Nutrition Corp. is thrilled to unveil its groundbreaking partnership with Six+One, a visionary move designed to significantly enhance the presence of its premier dietary supplement, unbuzzd, in preparation of the launch in the United States. This strategic alliance is more than just a collaboration; it's a bold step forward, leveraging Six+One's unparalleled branding and strategic expertise to redefine wellness. Renowned for its innovative work with brands like vitaminwater and Body Armor, Six+One brings a disruptive approach to the marketplace, emphasizing the importance of marketing a brand's purpose beyond its product. This ethos, which aligns perfectly with today's consumer desire to understand the 'why' behind a brand, sets the stage for a transformative journey for unbuzzd, promising to connect with audiences on a deeper, more meaningful level. Through this collaboration, Six+One has been retained to undertake a comprehensive brand development for unbuzzd, encompassing: establishing a brand personality, visual identity creation, packaging design and building the company website."

07:53 EDT Honeywell says on track to exceed $25B+ of capital deployment through 2025 - Plans to prioritize attractive bolt-on transactions between $1B-$7B. Also plans smaller, strategic investments that tuck-into ongoing business offerings. Says: Record backlog and improving short-cycle fundamentals to deliver strong results in 2024 and beyond; Improving business mix, commercial excellence, and productivity actions provide confidence in 2024 margin expansion guidance; Portfolio actions accelerating; continuing to execute on $25B+ capital deployment commitment. Comments taken from investor presentation slides.

07:49 EDT Union Pacific sees FY24 capital plan $3.4B

07:38 EDT Streamline Health signs second enterprise client - Streamline Health Solutions announced that it has expanded its partnership with a 5 facility, 700-bed Oracle EHR based health system. The system has been using RevID's automated charge reconciliation for more than 2 years and has elected to add eValuator's code auditing technology for improved pre-bill revenue integrity. "We are ecstatic to be able to help our client expand the capabilities of their talented team to ensure accurate compensation for all of the care provided at their world-class healthcare facilities" stated Ben Stilwill, President and Chief Executive Officer, Streamline. "We look forward to leveraging the synergistic impact of RevID's charge reconciliation and eValuator's pre-bill code auditing technology in one health system to improve their revenue cycle."

07:35 EDT Soligenix extends patent protection for Filovirus Vaccine platform - Soligenix announced that it has received notice of intent to grant additional patents based on its patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines" in the United Kingdom and South Africa, with other international jurisdictions pending. The company has previously announced multiple issued patents within the same patent family in the United States. The allowed claims are directed to unique, proprietary compositions and methods related to combinations of glycoprotein antigens with nanoemulsion adjuvants comprising sucrose fatty acid esters prior to lyophilization. The described vaccine platform has previously been successfully applied to mono-, bi- and tri-valent candidates for Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus, including monovalent vaccines SuVax (targeting Sudan ebolavirus) and MarVax (targeting Marburg marburgvirus).

07:33 EDT Anywhere Real Estate sees 'at least' $100M in cost savings in 2024 - "The company expects to realize cost savings of at least $100 million in 2024. The company expects our operating Free Cash Flow excluding one-time items to be modestly positive in 2024 as favorable working capital, robust savings programs, and our cash management discipline will help counterbalance another tough year in housing. And as a reminder, we have over $100 million of one-time payments anticipated this year between the $73.5 million class action litigation payment and the $39 million legacy California tax matter."

07:32 EDT Tradeweb Markets sees FY24 expenses $755M-805M, trending toward range top - Sees adjusted expenses: $755 - 805M, trending toward top end of range; Acquisition and Refinitiv Transaction related depreciation and amortization expense: $142M; Assumed non-GAAP tax rate: ~ 24.5% - 25.5% Cash costs of non-acquisition capital expenditures and capitalized software development: $75 - 83M LSEG Market Data Contract Revenue: ~$80M or ~$90M in 2025.

07:30 EDT Microbix collaborator Labquality introduces lab accreditation program - Microbix Biosystems announces that Labquality is presenting results of its use of Microbix Quality Assessment Products for accreditation of clinical labs for conducting molecular tests for antimicrobial-resistant strains of M. genitalium, a common sexually-transmitted infection. The poster presentation of results will be made at ECCMID 2024, the European Congress of Clinical Microbiology and Infectious Diseases taking place in Barcelona, Spain from April 27 to 30, 2024. The poster is titled "Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme" and was authored by scientists from both Labquality and Microbix. Mgen is a common STI in both men and women who have been sexually-active. Left untreated, Mgen is known to cause chronic health problems in women, such as chronic pain, ectopic pregnancy, infertility, and pelvic inflammatory disease, and non-gonococcal urethritis in men. As many as 50% of Mgen infections can be resistant to first-line antibiotic treatments. Tests for Mgen were not commonly conducted until the past several years, in part due to the unavailability of controls to assess and validate the accuracy of tests for antibiotic-susceptible and AMR strains of this bacteria. As testing for Mgen and AMR Mgen infections becomes more widespread, external quality assessment programs are needed to evaluate the proficiency of clinical labs and provide them accreditation to test patient-samples. The poster presents results of a Labquality program evaluating the proficiency of 38 clinical labs in their use of 16 different MDx assays. Each clinical lab was evaluated for its ability to detect Mgen, and an Mgen-related marker of resistance to macrolide antibiotics. It was found that the Microbix Mgen QAPs were well-suited for this usage, the performance of labs and assays was excellent, specific reporting guidelines are needed to avoid errors, and there is a need for such an EQA program to support Mgen testing. Microbix developed its Mgen QAPs to resemble patient specimens, support the whole testing process, and contain all possible MDx test targets - buffered and desiccated onto a Copan FLOQSwab to ensure multi-year product stability at room temperature. The pilot EQA program confirmed the performance of these QAPs across all clinical labs, instrument platforms, and assays. These Mgen QAPs are now available from Microbix as part of its PROCEEDx FLOQ or REDx FLOQ catalogue of products.

07:28 EDT Regeneron, Mammoth collaborate to purse next-generation gene editing - Regeneron Pharmaceuticals and Mammoth Biosciences announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. Regeneron is developing adeno-associated viral vectors using antibody-based targeting to enhance delivery of genetic medicine payloads to specific tissues and cell types. Mammoth is developing novel ultracompact nucleases and associated gene editing systems, with a variety of editing functionalities at a significantly smaller size than other CRISPR-based systems, including first generation Cas9 nucleases. By leveraging Regeneron's expertise in AAV and antibody engineering and Mammoth's expertise in ultracompact gene editing systems, the teams will endeavor to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.

07:26 EDT ParaZero integrates safety tech into Draganfly Commander 3XL drones - ParaZero Technologies (PRZO) announced a strategic collaboration with Draganfly (DPRO) integrating its advanced safety technology into Draganfly's Commander 3XL drones. This enhancement is set to significantly boost the safety and reliability of UAVs in crucial applications and emergency operations. By incorporating ParaZero's state-of-the-art safety technology into Draganfly's Commander 3XL drones, the collaboration ensures enhanced safety for urban and wilderness operations.

07:25 EDT Optinose provides corporate update on XHANCE launch - Optinose announced corporate updates detailing its commercial plans and expectations for XHANCE following the recent FDA approval of a new indication for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 year of age and older. The Company will host an investor call at 10:00 a.m. Eastern Time today to discuss its commercial strategy and financial outlook. "The recent FDA approval of XHANCE as the first and only approved drug treatment for chronic sinusitis is a landmark achievement," said Ramy Mahmoud, MD, MPH, CEO of Optinose. "Because we plan to leverage our current commercial infrastructure, including 75 sales territories, we expect to need limited incremental spend to effectively reach the estimated 3 million patients with chronic sinusitis who are cared for by ENT and Allergy specialists. To prepare for an effective launch, we have recently optimized our sales alignment towards a chronic sinusitis call target universe and partnered with a specialty pharmacy hub to improve patient and physician office experience and increase prescription fill and reimbursement rates. Based on our market analysis, we believe that our base planned efforts focused on a specialty prescriber audience can grow XHANCE peak year net revenues to more than $300 million and allow Optinose to produce positive income from operations for full year 2025. With incremental investments in the future, we believe the market opportunity could be expanded to over 30 million patients through outreach to the 7 million patients being treated by primary care physicians and by direct-to-consumer activation of the 20 million patients who report suffering from chronic sinusitis symptoms," he concluded. Financial Outlook: XHANCE Net Revenue: The Company expects peak XHANCE net revenues to exceed $300 million based on its current promotional focus on a specialty audience of mostly ENT and Allergy specialists. Income from Operations: The Company expects to produce positive income from operations for full year 2025.

07:24 EDT Tilray's Sweetwater Brewing unveils modern rebrand - SweetWater Brewing Company, a subsidiary of Tilray Brands, announced a design refresh to make the Sweetwater brand more impactful, cohesive, and memorable to consumers. SweetWater's updated portfolio of beers is available now across the Southeast and in select national markets.

07:21 EDT Hookipa Pharma announces Phase 2/3 trial design for HB-200 - HOOKIPA Pharma announced its final pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab. The Phase 2/3 trial design and protocol are based on alignment with the U.S. Food and Drug Administration following the Company's Type C meeting with the FDA. The seamless Phase 2/3 trial is for the investigational product HB-200 in combination with pembrolizumab for the treatment of patients with Human Papillomavirus 16-positive recurrent/metastatic PD-L1 CPS greater than or equal to 20 oropharyngeal squamous cell carcinoma in the first line setting. The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.

07:21 EDT Draganfly integrates ParaZero Safety Technology into commander 3XL drones - Draganfly (DPRO) announces a strategic collaboration with ParaZero Technologies (PRZO). The integration of Draganfly and ParaZero technology is enhancing safety for UAV operations in projects such as Mass General Brigham's Home Hospital UAV Delivery Pilot -one of the country's leading home healthcare initiatives-and Squamish Search and Rescue, operating in one of the world's busiest outdoor sporting and recreation regions. The integration of ParaZero into Draganfly's Commander 3XL supports enhanced safety for flight operations over people and beyond visual line of sight. "Working with ParaZero signifies our commitment to advancing UAV safety and operational capabilities," said Cameron Chell, CEO of Draganfly. "As we expand what UAVs can achieve in critical missions, ensuring the highest safety standards is paramount. Our work together will help us provide emergency responders with a safer, more reliable aerial support tool."

07:18 EDT Kirby CEO says 'off to a solid start' in 2024 - Commenting on the outlook for the remainder of 2024, Mr. Grzebinski said, "We are off to a solid start in 2024 and have a favorable outlook for the remainder of the year. Our balance sheet is strong, and we expect to generate significant free cash flow despite high levels of capex this year and expect to use the majority of free cash flow for share repurchases. We see favorable markets continuing and expect our businesses will produce improving financial results as we move through this year." In inland marine, our 2024 outlook anticipates positive market dynamics with steady customer demand and limited new barge construction in the industry. In addition to this, many industry units are scheduled for maintenance. With these favorable market conditions, we expect our barge utilization rates to be in the low to mid-90% range throughout the year. To support our ability to meet customer demand, we have recently entered into an agreement to acquire 13 barges, including three specialty barges, and two high horsepower boats from an undisclosed seller. Overall, inland revenues are expected to grow in the mid to high single digit range on a full year basis. However, a potential recession with a drop in demand could impact expected growth. The Company expects operating margins to gradually improve during the year and average around 20% for the full year. In coastal marine, strong customer demand is expected throughout the year with barge utilization in the low to mid-90% range. With major shipyards and ballast water treatment installations concluding in the first half of the year, revenues for the full year are expected to increase in the high single to low double digits range compared to 2023. Coastal operating margins are expected to be in the high single to low double-digit range on a full year basis. In the distribution and services segment, despite the uncertainty from volatile commodity prices, we expect incremental demand for products, parts, and services in the segment. In commercial and industrial, the demand outlook in marine repair is strong while on highway is somewhat weak with the exception of refrigeration products and services. In power generation we anticipate continued strong growth as data center demand and the need for backup power is very strong. In oil and gas, activity levels are lower but seem to be bottoming. Our manufacturing backlog does provide stable levels of activity through most of 2024. We do anticipate extended lead times for certain OEM products to continue contributing to a volatile delivery schedule of new products in 2024 and into 2025. Overall, the Company expects segment revenues to be flat to slightly down on a full year basis with operating margins in the mid to high-single digits but slightly lower year-over-year due to mix. Kirby expects to generate net cash provided from operating activities of $600 million to $700 million in 2024 and capital spending is expected to range between $290 million to $330 million. Approximately $190 million to $240 million is associated with marine maintenance capital and improvements to existing inland and coastal marine equipment, including the remaining ballast water treatment systems on some coastal vessels, and facility improvements. Approximately $90 million is associated with growth capital spending in both our businesses.

07:12 EDT Nasdaq raises quarterly dividend 9% to 24c per share - The Board of Directors of Nasdaq has declared a regular quarterly dividend of $0.24 per share on the company's outstanding common stock, a 9% increase from the previous quarter. The dividend is payable on June 28, 2024 to shareholders of record at the close of business on June 14, 2024. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors.

07:09 EDT American Airlines reduces total debt by $950M in Q1 - Strengthening the balance sheet remains a top priority for American. In the first quarter, the company reduced total debt by nearly $950 million and has now achieved more than $12 billion, or over 80%, of its goal of reducing total debt by $15 billion by the end of 2025.

07:04 EDT Stericycle on track to realize $40M-$45M in-year cost savings - Completed previously disclosed workforce reduction in the first quarter of 2024 and are on track to realize an estimated $40-$45 million of in-year cost savings.

06:57 EDT TechnipFMC sees 2024 CapEx $275M - Sees 2024 Subsea segment revenue $7.2B-$7.6B and surface technologies segment revenue $1.2B-$1.35B. Consensus for total 2024 revenue is $8.73B.

06:41 EDT Royal Caribbean sees FY24 fuel expenses $1.18B - Sees FY24 fuel consumption 1.72M metric tons.

06:33 EDT Perrigo to sell HRA Pharma Rare Diseases business for EUR 275M - Perrigo announced that pharmaceutical company Esteve Healthcare has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to EUR 275M, consisting of an upfront cash payment of EUR 190M and up to EUR 85M in potential earnout payments based on the Rare Diseases business achieving certain sales milestones. Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by Esteve and enter into a definitive agreement with Esteve for the sale of the Rare Diseases business. The proposed final transaction is expected to close during the third quarter of 2024, subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals.

06:27 EDT Parsons awarded $63M contract from U.S. Air Force - Parsons announced that the company has been awarded a $63M, firm-fixed-price contract modification to its Recovery of Airbase Denied by Ordnance production contract by the U.S. Air Force Life Cycle Management Center. This modification brings the total number of Air Force RADBO systems to 29.

06:14 EDT Chevron affiliate Tengizchevroil commences operations at oil field in Kazakhstan - Chevron announced that its 50% owned affiliate Tengizchevroil has safely commenced operations at its Wellhead Pressure Management Project, or WPMP, at the Tengiz oil field in Kazakhstan. TCO achieved this milestone by converting its first metering station at Tengiz to low pressure and activating the associated Pressure Boost Facility, or PBF. This marks important progress for TCO's overall expansion project at Tengiz. The WPMP is designed to maintain the existing processing plants' full capacity by lowering the flowing pressure at the wellheads and then boosting the pressure to the existing plants.

06:13 EDT WNS Holdings CFO Sanjay Puria stepping down, Arijit Sen succeeds - WNS Holdings has appointed Arijit Sen, the company's Corporate Financial Controller, as CFO effective July 25, succeeding Sanjay Puria who has chosen to step down for family reasons. Sanjay will remain with WNS in an advisory role until April 24, 2025 to help ensure a seamless transition. Arijit Sen joined the WNS finance team 15 years ago, and during his tenure has managed each of the company's corporate finance functions including Treasury, FP&A, M&A, Tax, and Controllership. Prior to joining WNS, Sen worked at Accenture as a management consultant in corporate strategy and business transformation.

06:09 EDT FirstCash outlook for 2024 'continues to be highly positive' - The company's outlook for 2024 continues to be highly positive, with expected year-over-year growth in revenue and earnings in all segments driven by the continued growth in earning asset balances coupled with recent store additions.

06:07 EDT Deutsche Bank makes progress toward EUR 25B-EUR 30B in optimizations by 2025 - The company said, "Capital efficiency: Deutsche Bank delivered RWA reductions of a further EUR 2 billion during the quarter through securitization and data and process improvements. As a result, cumulative RWA reductions from capital efficiency measures reached EUR 15 billion, representing further progress toward the bank's objective of EUR 25-30 billion in optimizations by 2025. The bank made progress on its share repurchase program launched on March 4, 2024; as at April 19, 2024, the bank had repurchased 20.6 million shares for a total of EUR 283 million. The bank anticipates materially completing the current program by the end of the first half of 2024."

06:06 EDT ImmunityBio announces overall survival results in QUILT 3.055 study - ImmunityBio announced overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy and standard-of-care chemotherapy to be discussed during the upcoming conference call. The results continue to reinforce ImmunityBio's belief in the unique mechanism of action of ANKTIVA and its potential efficacy as a next-generation immunotherapy across multiple solid and liquid tumor types. In NSCLC patients who relapsed or were refractory to checkpoint inhibitors, ANKTIVA was administered together with the same checkpoint inhibitor. The addition of ANKTIVA resulted in the rescue of the checkpoint therapy efficacy, with significant prolongation of overall survival. These positive results were noted regardless of the patient's PD-L1 status, consistent with the mechanism of action of ANKTIVA in activating and proliferating natural killer cells, and stimulating CD8+ Killer Memory T cells. This prolongation of survival in NSCLC following checkpoint failure is consistent with ImmunityBio's findings of durable complete responses following BCG failure in NMIBC. A meeting with the FDA has been scheduled for June to discuss the company's overall survival results in PD-L1 negative and positive patients and registration plans for 2nd-line and 3rd-line NSCLC patients whose cancer did not respond or continue to respond to checkpoint therapy and for whom few alternative therapies are available. The overall survival data of patients enrolled in QUILT 3.055, a basket trial across multiple tumor types, in which checkpoint inhibitors failed, will be discussed, along with the status of launch readiness for ANKTIVA for its recently approved indication in NMIBC on an investor conference call Friday, April 26 at 8 am PDT/11 am EDT.

06:05 EDT TRI Pointe sees Q2 home delivery 1,500-1,600 homes at average price $670K-$680K - Expects Q2 homebuilding gross margin percentage of 22.5%-23.5% and anticipates SG&A expense as a percentage of home sales revenue of 11.0%-11.5%.

05:28 EDT Medivir announces MIV-711 granted RPDD, ODD - Medivir announced that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease Designation, or RPDD, as well as Orphan Drug Designation, or ODD, for the treatment of Legg-Calve-Perthes Disease, or LCPD. With a RPDD, MIV-711 qualifies to receive fast track review and upon marketing approval in LCPD, the company may be eligible to receive a Priority Review Voucher from the FDA. The voucher can be redeemed to receive priority review for any subsequent marketing application or may be sold to another company for their use.

05:20 EDT Micron enters PMT for $6.1B in funding to support U.S. memory manufacturing - Micron and the Biden-Harris Administration announced that they have signed a non-binding preliminary memorandum of terms, or PMT, for $6.1B in funding under the CHIPS and Science Act to support memory manufacturing in Idaho and New York. The CHIPS and Science Act grants of $6.1B will support Micron's plans to invest approximately $50B in gross capex for U.S. domestic leading-edge memory manufacturing through 2030. These grants and additional state and local incentives will support the construction of one memory manufacturing fab to be co-located with the company's existing R&D facility in Boise, Idaho and the construction of two memory fabs in Clay, New York. The investments announced represent the first step toward Micron's vision of both a R&D and manufacturing center in Boise, Idaho and a four-fab manufacturing complex in Clay, New York to be built over the next 20-plus years with potential investment totaling up to $125B. These investments will support Micron's objective to grow its memory bit supply in line with long-term industry bit demand growth. Micron retains flexibility under the PMT to remain responsive to market conditions over time. In addition to the announced $6.1B in grants, workforce grants to support Micron's efforts to build a vibrant talent pipeline are also being finalized. In addition to the CHIPS grants, Micron expects to benefit from the U.S. Treasury Department's Investment Tax Credit, which provides a credit of 25% for qualified capital investments. The state of New York has made up to $5.5B available in incentives over the life of the project, comprised of a 5% New York investment tax credit on qualified capital investments and 7.5% of eligible non-construction labor costs. Micron and the state of New York also established the Green CHIPS Community Investment Fund to support community and workforce development in the region. The company will also benefit from an incentive package in the state of Idaho, including reduced state taxes related to the project and substantial investments in semiconductor workforce training programs. These federal and state incentives, combined with projected power cost advantages, along with R&D and manufacturing co-location synergies, enable Micron to achieve cost-competitive memory manufacturing in the U.S. Micron's planned semiconductor manufacturing facilities are expected to create approximately 75,000 domestic jobs over the next 20-plus years. In Idaho, this includes 2,000 Micron jobs, 4,500 construction jobs and 15,000 indirect jobs. In New York, this includes 9,000 Micron jobs, 4,500 construction jobs and 40,000 indirect jobs. The two projects, as planned, will represent the single largest private investments ever made in the states of Idaho and New York. Micron's Idaho fab and two New York fabs are expected to help the U.S. grow its share of advanced memory manufacturing from less than 2% today to approximately 10% by calendar year 2035. Micron initiated construction on its Boise fab in October of calendar year 2023. The fab will be co-located with Micron's world-class R&D center to enhance operational efficiency, accelerate technology deployment and improve time to market for leading-edge products. The Idaho fab is expected to come online and be operational in calendar year 2025, with DRAM output starting in calendar year 2026 and ramping in line with market demand over the second half of the decade. In New York, preliminary design, field studies and permitting applications, including NEPA, are underway for the project. Construction of the first fab is expected to begin in calendar year 2025 and to come online and contribute to output in calendar year 2028, ramping in line with market demand over the next decade. In addition to the Idaho and New York projects, Micron has submitted an application under the CHIPS program to the Department of Commerce to modernize its Manassas, Virginia fab for the production of long-lifecycle chips to support customer demand in areas such as automotive, industrial, aerospace and defense. The PMT provides that the award is subject to due diligence and the negotiation and signing of a definitive agreement with the Department of Commerce, and the disbursement of funds will be conditioned upon the achievement of certain milestones and other requirements. The additional terms of the agreement remain confidential.